A. S. Goncharov
Research Subjects
A. S. Goncharov has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- A. V. Kapashin
Valenta Pharm JSC
3 shared publications - Aleksander A. Globenko
Valenta Pharm JSC
3 shared publications - Maksim A. Pasko
Valenta Pharm JSC
3 shared publications - Alexander V. Grigoriev
CSU “Analytical Spectrometry
2 shared publications - I. S. Goncharov
Serta Clinic LLC
2 shared publications - Konstantin A. Zakharov
Scientific Research Center Eco-Safety LLC
2 shared publications
Latest Publications
- Open Access
- 23 August 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 18-26
Evaluation of the pharmacological effect of Antareit® (oral suspension, 800 mg/10 ml) in healthy volunteers
The aim of the study was to evaluate the pharmacodynamic equivalence of the drugs Antareit® (oral suspension, 800 mg/10 ml; Valenta Pharm JSC, Russia) and Riopan® (chewable tablets, 800 mg; Takeda GmbH, Germany) based on their antacid activity.Material and methods. An open-label, two-period two-sequence crossover study was conducted to evaluate the pharmacodynamics of the test drug Antareit® (oral suspension, 800 mg/10 ml) and the reference drug Riopan® (chewable tablets, 800 mg), both administered as a single oral dose of 1600 mg. A total 50 healthy volunteers were randomized into two groups (n = 25) according to treatment sequence with a 7-day washout period between administrations. Gastric pH was continuously monitored for 1 hour after dosing using an intragastric pH probe placed in the gastric corpus. The main pharmacodynamics parameter was the area under the pH-time curve above baseline (AUCABL). Equivalence was determined by calculating the 90 % confidence interval (CI) for the ratio of marginal means of AUCABL between the two formulations. Safety was assessed through monitoring of adverse events (AEs), physical examinations, vital signs measurement, laboratory tests and electrocardiogram (ECG) findings.Results. A total of 48 out of 50 randomized subjects completed both periods of the study. Two volunteers discontinued before receiving the drug in period 2. The 90 % CI for the AUCABL was calculated using a mixed-effects model (MIXED) and a generalized linear model (GLM). The marginal mean AUCABL values were 68,81 for Antareit®, oral suspension, 800 mg/10 ml and 68,42 for Riopan®, chewable tablets, 800 mg based on GLM analysis. The AUCABL ratio (test drug / reference drug) was 100,57 % (90 % Cl: 82,44–122,69 %), indicating non-inferiority. Three AEs occurred in two subjects: two cases of rhinorrhea in one volunteer and one case of somnolence following drug administration. There were no statistically significant differences in the frequency of AEs between treatments.Conclusion. The study established pharmacodynamic equivalence between the test drug Antareit®, oral suspension, 800 mg/10 ml and the reference drug Riopan®, chewable tablets, 800 mg. The safety profiles of both treatments were found to be similar, with no significant differences observed in either the incidence or severity of AE.
- 23 August 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 18-26
Open AccessEvaluation of the pharmacological effect of Antareit® (oral suspension, 800 mg/10 ml) in healthy volunteers
The aim of the study was to evaluate the pharmacodynamic equivalence of the drugs Antareit® (oral suspension, 800 mg/10 ml; Valenta Pharm JSC, Russia) and Riopan® (chewable tablets, 800 mg; Takeda GmbH, Germany) based on their antacid activity.Material and methods. An open-label, two-period two-sequence crossover study was conducted to evaluate the pharmacodynamics of the test drug Antareit® (oral suspension, 800 mg/10 ml) and the reference drug Riopan® (chewable tablets, 800 mg), both administered as a single oral dose of 1600 mg. A total 50 healthy volunteers were randomized into two groups (n = 25) according to treatment sequence with a 7-day washout period between administrations. Gastric pH was continuously monitored for 1 hour after dosing using an intragastric pH probe placed in the gastric corpus. The main pharmacodynamics parameter was the area under the pH-time curve above baseline (AUCABL). Equivalence was determined by calculating the 90 % confidence interval (CI) for the ratio of marginal means of AUCABL between the two formulations. Safety was assessed through monitoring of adverse events (AEs), physical examinations, vital signs measurement, laboratory tests and electrocardiogram (ECG) findings.Results. A total of 48 out of 50 randomized subjects completed both periods of the study. Two volunteers discontinued before receiving the drug in period 2. The 90 % CI for the AUCABL was calculated using a mixed-effects model (MIXED) and a generalized linear model (GLM). The marginal mean AUCABL values were 68,81 for Antareit®, oral suspension, 800 mg/10 ml and 68,42 for Riopan®, chewable tablets, 800 mg based on GLM analysis. The AUCABL ratio (test drug / reference drug) was 100,57 % (90 % Cl: 82,44–122,69 %), indicating non-inferiority. Three AEs occurred in two subjects: two cases of rhinorrhea in one volunteer and one case of somnolence following drug administration. There were no statistically significant differences in the frequency of AEs between treatments.Conclusion. The study established pharmacodynamic equivalence between the test drug Antareit®, oral suspension, 800 mg/10 ml and the reference drug Riopan®, chewable tablets, 800 mg. The safety profiles of both treatments were found to be similar, with no significant differences observed in either the incidence or severity of AE.
- Open Access
- 22 January 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 32-40
Study of antacid effect of the drug Antareit® in healthy volunteers
The aim. Study of pharmacodynamic parameters and confirmation of pharmacodynamic equivalence (bioequivalence) of the drugs Antareit® (INN: magaldrate), chewable tablets, 800 mg (Valenta Pharm JSC, Russia) and Riopan (INN magaldrate), chewable tablets, 800 mg (Takeda GmbH, Germany). Material and methods. An open randomized crossover study was conducted to investigate the pharmacodynamics of the study drug Antareit® and the reference drug Riopan, assessing their bioequivalence after taking 2 chewable tablets of the study or reference drug 3 times a day. The study involved 40 healthy volunteers who were randomized into 2 groups of 20 people depending on the sequence of drug administration in study periods I and II. Intragastric acidity was measured with a pH-probe within 30 minutes before and for one hour after taking the study drugs. Based on the data obtained, 90% confidence intervals (CI) were calculated for the pharmacodynamic parameter AUCABL, reflecting the area above the baseline pH. The safety of the study drugs was assessed by the frequency and severity of adverse events (AEs). Results. Statistical analysis showed that the 90% CI for the ratio of the mean values of the AUC ABL parameter of the study drug to the reference drug did not fall below 80% (90% CI: 80.55–119.49). During the study, 18 adverse events (AEs) were reported in 15.4% (6 of 39) of volunteers in the safety population, and there were no statistically significant differences in the incidence of AEs between groups, nor in the incidence of AEs depending on the drug taken. Conclusion. The studied drugs are pharmacodynamically equivalent and have a similar safety profile when administered repeatedly.
- 22 January 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 32-40
Open AccessStudy of antacid effect of the drug Antareit® in healthy volunteers
The aim. Study of pharmacodynamic parameters and confirmation of pharmacodynamic equivalence (bioequivalence) of the drugs Antareit® (INN: magaldrate), chewable tablets, 800 mg (Valenta Pharm JSC, Russia) and Riopan (INN magaldrate), chewable tablets, 800 mg (Takeda GmbH, Germany). Material and methods. An open randomized crossover study was conducted to investigate the pharmacodynamics of the study drug Antareit® and the reference drug Riopan, assessing their bioequivalence after taking 2 chewable tablets of the study or reference drug 3 times a day. The study involved 40 healthy volunteers who were randomized into 2 groups of 20 people depending on the sequence of drug administration in study periods I and II. Intragastric acidity was measured with a pH-probe within 30 minutes before and for one hour after taking the study drugs. Based on the data obtained, 90% confidence intervals (CI) were calculated for the pharmacodynamic parameter AUCABL, reflecting the area above the baseline pH. The safety of the study drugs was assessed by the frequency and severity of adverse events (AEs). Results. Statistical analysis showed that the 90% CI for the ratio of the mean values of the AUC ABL parameter of the study drug to the reference drug did not fall below 80% (90% CI: 80.55–119.49). During the study, 18 adverse events (AEs) were reported in 15.4% (6 of 39) of volunteers in the safety population, and there were no statistically significant differences in the incidence of AEs between groups, nor in the incidence of AEs depending on the drug taken. Conclusion. The studied drugs are pharmacodynamically equivalent and have a similar safety profile when administered repeatedly.
- Open Access
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 80-88
Pharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio®
Objective: to study the pharmacokinetic parameters and safety of Dorsumio® (mirtazapine + tizanidine, extended-release tablets, 15 mg + 6 mg, JSC Valenta Pharm, Russia) taken once by healthy volunteers in comparison with Calixta®, a monocomponent drug (INN: Mirtazapine, filmcoated tablets, 30 mg, Belupo, Drugs and Cosmetics d.d., Republic of Croatia) and Sirdalud® MR (INN: Tizanidine, modified-release capsules, 6 mg, Novartis Pharma AG, Switzerland) with an evaluation of their drug interactions when taken concomitantly or separately.Material and methods. A two-stage, randomized, comparative cross-over study of the pharmacokinetics and safety of the complex drug Dorsumio® was conducted. In the first stage, volunteers alternated between taking one or two tablets of the study drug in two administration periods; in the second stage, subjects alternated between taking the reference monodrugs Calixta® and Sirdalud® MR alone and in a joint combination in three administration periods. A total of 38 volunteers were randomized into the study, of which 14 subjects participated in the first and 24 in the second stage of the study. Quantitative levels of mirtazapine and tizanidine were determined by high-performance liquid chromatography with tandem mass spectrometry. Based on the data obtained, the main pharmacokinetic parameters reflecting the bioavailability of each drug were calculated, and the mutual influence of their combination on pharmacokinetics was also studied. During the study, vital signs and laboratory parameters of the subjects were monitored, and the occurrence of adverse events (AEs) and serious AEs was recorded.Results. A two-fold increase in the dose of the combination drug Dorsumio® resulted in a comparable increase in the pharmacokinetics of the individual drugs. There was no significant reciprocal effect of mirtazapine and tizanidine on their pharmacokinetic parameters. In one of the subjects participating in the second stage of the study, two mild side effects were registered after the joint use of Calixta® and Sirdalud® MR that did not require medical intervention and resolved on their own without health consequences.Conclusion. There were no differences in the safety profile of the combined use of mirtazapine and tizanidine in the form of a free or fixed combination. It was shown that the investigated drug combination had no mutual influence on the pharmacokinetics of the individual components.
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 80-88
Open AccessPharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio®
Objective: to study the pharmacokinetic parameters and safety of Dorsumio® (mirtazapine + tizanidine, extended-release tablets, 15 mg + 6 mg, JSC Valenta Pharm, Russia) taken once by healthy volunteers in comparison with Calixta®, a monocomponent drug (INN: Mirtazapine, filmcoated tablets, 30 mg, Belupo, Drugs and Cosmetics d.d., Republic of Croatia) and Sirdalud® MR (INN: Tizanidine, modified-release capsules, 6 mg, Novartis Pharma AG, Switzerland) with an evaluation of their drug interactions when taken concomitantly or separately.Material and methods. A two-stage, randomized, comparative cross-over study of the pharmacokinetics and safety of the complex drug Dorsumio® was conducted. In the first stage, volunteers alternated between taking one or two tablets of the study drug in two administration periods; in the second stage, subjects alternated between taking the reference monodrugs Calixta® and Sirdalud® MR alone and in a joint combination in three administration periods. A total of 38 volunteers were randomized into the study, of which 14 subjects participated in the first and 24 in the second stage of the study. Quantitative levels of mirtazapine and tizanidine were determined by high-performance liquid chromatography with tandem mass spectrometry. Based on the data obtained, the main pharmacokinetic parameters reflecting the bioavailability of each drug were calculated, and the mutual influence of their combination on pharmacokinetics was also studied. During the study, vital signs and laboratory parameters of the subjects were monitored, and the occurrence of adverse events (AEs) and serious AEs was recorded.Results. A two-fold increase in the dose of the combination drug Dorsumio® resulted in a comparable increase in the pharmacokinetics of the individual drugs. There was no significant reciprocal effect of mirtazapine and tizanidine on their pharmacokinetic parameters. In one of the subjects participating in the second stage of the study, two mild side effects were registered after the joint use of Calixta® and Sirdalud® MR that did not require medical intervention and resolved on their own without health consequences.Conclusion. There were no differences in the safety profile of the combined use of mirtazapine and tizanidine in the form of a free or fixed combination. It was shown that the investigated drug combination had no mutual influence on the pharmacokinetics of the individual components.